NCT03975218

Brief Summary

Stroke is a growing disease. It is the first pathology responsible for acquired handicap, the second of dementia and the second cause of death in the world. In France, they are the leading cause of death in women and the third cause in men. Sequelae and disabilities also represent a significant financial cost for health insurance. The early management of the treatment improves the patient's vital and functional prognosis. The ability of the patient to identify the signs of stroke requiring urgent consultation and proper orientation are therefore crucial for further management. The most common signs that patients must recognize are muscle weakness or sudden paralysis of an arm, leg or half of the body, asymmetry of the face, tingling, numbness of a hemi-body, speech or understanding, loss of vision of an eye or hemifield, disorder of the coordination of a hemi-body. The variety of clinical pictures complicates primary prevention. In this context, a 2010-2014 National Stroke Action Plan was undertaken with the aim, among other things, of developing information to prevent stroke and to limit its sequelae. In this plan, the attending physician must improve prevention in high-risk patients and be a link between the city and the hospital for follow-up. Several questions arise:

  • Are patients who are regularly followed by a general practitioner better educated on the signs of stroke / TIA and thus more able to give an appropriate warning?
  • What is the profile of patients who have not been affected by the different modes of primary prevention?
  • What are the effective means of information and those desired

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
18

participants targeted

Target at below P25 for all trials

Timeline
Completed

Started Jun 2019

Shorter than P25 for all trials

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

May 24, 2019

Completed
12 days until next milestone

First Posted

Study publicly available on registry

June 5, 2019

Completed
2 days until next milestone

Study Start

First participant enrolled

June 7, 2019

Completed
2 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

July 29, 2019

Completed
4 months until next milestone

Study Completion

Last participant's last visit for all outcomes

December 5, 2019

Completed
Last Updated

December 6, 2019

Status Verified

December 1, 2019

Enrollment Period

2 months

First QC Date

May 24, 2019

Last Update Submit

December 5, 2019

Conditions

Outcome Measures

Primary Outcomes (1)

  • Time until patient's care in the hospital after stroke's symptoms

    The delay between the observation of signs of stroke and specialized neurovascular management at the hospital will be measured. This measures the impact of physician's prevention on the management of stroke.

    Day 1

Secondary Outcomes (1)

  • Study the different effective means of primary prevention

    Day 1

Study Arms (1)

Patients with stroke

In addition to the usual care, the patient will have to complete a questionnaire analyzing the regularity of his follow-up by a physician.

Other: Patients With Stroke

Interventions

In addition to the usual care, the patient will have to complete a questionnaire analyzing the regularity of his follow-up by a physician.

Patients with stroke

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodNon-Probability Sample
Study Population

Patient hospitalized in the neurology / neurovascular department within the GHPSJ following a stroke (first episode or recurrence)

You may qualify if:

  • Patient whose age is ≥ 18 years
  • Patient hospitalized in the neurology / neurovascular department within the GHPSJ following a stroke (first episode or recurrence)
  • Francophone patient

You may not qualify if:

  • Patient with previously labeled cognitive impairment
  • Patient under tutorship or curatorship
  • Patient deprived of liberty
  • Patient unable to answer the questionnaire
  • Patient opposing participation in the study

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Groupe Hospitalier Paris Saint-Joseph

Paris, 75014, France

Location

MeSH Terms

Conditions

Stroke

Condition Hierarchy (Ancestors)

Cerebrovascular DisordersBrain DiseasesCentral Nervous System DiseasesNervous System DiseasesVascular DiseasesCardiovascular Diseases

Study Officials

  • Marie BRUANDET, MD

    Fondation Hôpital Saint-Joseph

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
observational
Observational Model
COHORT
Time Perspective
PROSPECTIVE
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

May 24, 2019

First Posted

June 5, 2019

Study Start

June 7, 2019

Primary Completion

July 29, 2019

Study Completion

December 5, 2019

Last Updated

December 6, 2019

Record last verified: 2019-12

Locations